High Security Online Ordering: 24/7 AvailabilityContact Form

Psilocybin In Canada

Where psilocybin stands in Canada today: the law, the legal routes to therapy, new Canadian research and what is changing around the world.
Illustration of glowing blue mushrooms in front of a maple leaf

A lot has changed since 2020. Canadians now have a few legal routes to psilocybin therapy, Canadian researchers are running new trials, and the first psilocybin medicine could be approved as early as 2027. Here is where things stand today.

At a glance

  • Psilocybin is still a controlled substance in Canada.
  • Since 2022, doctors can request psilocybin for seriously ill patients through Health Canada’s Special Access Program.
  • New Canadian trials are testing psilocybin for depression and anxiety.
  • No psilocybin medicine is approved anywhere yet, but the first could be approved in the U.S. in 2027.

Where the law stands

Illustration of scales balancing a mushroom and a medical cross, beside a document stamped with a maple leaf

Psilocybin and psilocin are still controlled substances in Canada. According to Health Canada, sadly despite all the current knowledge and positive clinical trials, no psilocybin medicine has been approved in Canada or anywhere else yet.

There are now three legal routes to psilocybin therapy:

  1. Clinical trials. Health Canada recommends these first. Trials test psilocybin under close medical supervision.
  2. The Special Access Program. Restored in January 2022, it lets a licensed doctor request psilocybin for a patient with a serious or life-threatening condition when other treatments have failed or aren’t suitable. Health Canada decides each request individually, and the psilocybin is taken with the practitioner present.
  3. Section 56 exemptions. Health Canada used these in 2020 to let the first patients use psilocybin. Today they have largely been replaced by the Special Access Program.

Provinces are setting their own rules too. In January 2023, Alberta became the first province to regulate psychedelic-assisted therapy: clinics need a licence, a psychiatrist must oversee treatment, and patients are supervised throughout.

Key moments

Research happening in Canada

Illustration of a lab flask, a mushroom and a rising bar chart

Microdosing for anxiety. In October 2025, the Kingston Health Sciences Centre Research Institute launched the first Health Canada-approved trial of daily, at-home microdosing. It is testing whether very small, non-psychedelic amounts of psilocybin can ease generalized anxiety, in up to 60 adults.

Natural psilocybin for depression. In September 2026, Health Canada authorized Vancouver’s Optimi Health to run a Phase 2 trial of naturally derived psilocybin for major depression, with up to 200 people at sites across Canada. It is expected to start in the first half of 2027.

Real-world experiences. Researchers in Montreal followed Canadians who received psilocybin therapy through compassionate-access exemptions. In their 2024 study of people living with cancer, anxiety, pain and quality of life improved after therapy. The authors call the results preliminary because only eight people completed the study.

Around the world

The largest psilocybin trials so far come from Compass Pathways. In its second Phase 3 trial of 581 people with treatment-resistant depression, 39% of those on the highest dose had a meaningful drop in symptoms by week 6 and kept that benefit through week 26. The company expects to finish its FDA application by the end of 2026 and hopes for approval in 2027.

Not every result is a clear win. A German trial published in JAMA Psychiatry in 2026 missed its main goal, although depression scores improved more with psilocybin in the follow-up analyses. Researchers agree that larger and longer studies are still needed.

Elsewhere, access keeps growing. Since July 2023, authorised psychiatrists in Australia can prescribe psilocybin for treatment-resistant depression, and in the U.S., Oregon and Colorado now license supervised psilocybin services for adults.

On Parliament Hill

In June 2026, Saskatoon MP Corey Tochor introduced Bill C-286, a private member’s bill that would allow psilocybin to be used for medical treatment. It has had its first reading but has not yet been scheduled for debate, so any change is likely some way off.

Videos

Recommended magic mushrooms

Shop dried magic mushrooms at ShroomTeam

Keep reading